HLBHLB

HLB remains loss-making with heavy debt, even as its share price has rebounded over the past month and a US drug launch is being prepared.

HLB reported trailing twelve-month revenue of about ₩97.5B against an operating loss of about ₩98.1B and a net loss of about ₩213.5B to H1 2026. Borrowings of about ₩277.2B exceed cash of about ₩26.4B, and free cash flow is negative. The shares closed at ₩39,250 on 2026-10-26, up 28.5% over one month but down 13.8% over one year.

What stands out

• Revenue has been volatile: it rose 23.6% in 2025 after falling 76.1% in 2023, while operating losses have stayed large in every year shown from 2021 to 2025.
• Liabilities are 114.9% of equity and the company has no reported dividend yield, with price-to-book at 15.2 and no meaningful earnings-based valuation because profits are negative.
• Foreign investors reduced holdings from 18.2% to 13.3% over about 60 days, and foreign net selling of about ₩131.7B over 20 days was offset by retail buying.
• News coverage centres on the company's Elevar unit preparing a US launch of a bile duct cancer drug, presenting results at ESMO, and on the Tetrapos consumer product expanding offline retail.
• Recent filings include several convertible bond and conversion price adjustments, plus a derivatives trading loss disclosed on 2026-08-14.

What to watch

• The next filed results and any update on the cash position and borrowings, given the negative free cash flow.
• Clinical and regulatory news on the drugs in the pipeline, including the US Phase 3 eye drug results mentioned in press coverage and the planned US launch.
• Further convertible bond conversions or price adjustments, and whether insider or major-holder share activity continues.